VBVadsala Baskaran

Vadsala Baskaran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vadsala Baskaran has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Carriage of Streptococcus pneumoniae in adults hospitalised with community-acquired pneumonia

    by Louise Lansbury, Tricia M. McKeever, Hannah Lawrence, Harry Pick, Vadsala Baskaran, Rochelle C. Edwards-Pritchard, Deborah Ashton, Chamira Rodrigo, Priya Daniel, David Litt, et al.


  • Open Access

    Incidence of cognitive impairment and dementia after hospitalisation for pneumonia: a UK population-based matched cohort study

    by Christos V. Chalitsios, Vadsala Baskaran, Rowan H. Harwood, Wei Shen Lim, Tricia M. McKeever

    Background: Survivors of common infections may develop cognitive impairment or dementia; however, the risk of these conditions in people hospitalised with pneumonia is not well established.Methods: A matched cohort study was conducted using Hospital Episode Statistics (HES) data linked to the Clinical Practice Research Database (CPRD). Adults with the first International Classification of Diseases (10th Revision) code for pneumonia recorded in the HES between 1 July 2002 and 30 June 2017 were included, and up to four controls without hospitalisation for pneumonia in the CPRD were matched by sex, age and practice. Cognitive impairment and dementia incidence rates were calculated and survival analysis was performed comparing those hospitalised with pneumonia to the general population.Results: The incidence rates of cognitive impairment and dementia were 18 (95% CI 17.3–18.7) and 13.2 (95% CI 13–13.5) per 1000 person-years among persons previously hospitalised with pneumonia and the matched cohort respectively. People previously hospitalised with pneumonia had 53% higher incidence of cognitive impairment and dementia (adjusted hazard ratio (aHR) 1.53, 95% CI 1.46–1.61) than their matched cohort. The highest incidence was observed within 1 year of hospitalisation for pneumonia compared to the general population (aHR 1.89, 95% CI 1.75–2.05). Age modified the effect of hospitalisation for pneumonia on cognitive impairment and dementia such that the size of effect was stronger in people between 45 and 60 years old (p-value for interaction <0.0001).Conclusion: Cognitive impairment and dementia are more likely to be diagnosed in people who have been hospitalised for pneumonia, especially in the first year after discharge, than in the general population.


  • Effects of tobacco smoking on recurrent hospitalisation with pneumonia: a population-based cohort study

    by Vadsala Baskaran, Wei Shen Lim, Tricia M McKeever

    The incidence of and risk factors for recurrent hospitalisation for pneumonia were investigated using data from Hospital Episode Statistics, linked to a UK primary care database. Within 90 days and 1 year of follow-up, 1733 (3.1%) and 5064 (9.0%), developed recurrent pneumonia respectively. Smoking status at the time of hospitalisation with index pneumonia was associated with the risk of readmission with recurrent pneumonia within a year of discharge: current versus never smokers: adjusted subhazard ratio (sHR) 1.42, 95% CI 1.32 to 1.53, p<0.001, and ex smokers versus never smokers: adjusted sHR 1.24, 95% CI 1.15 to 1.34, p<0.001. Other independent risk factors associated with recurrent pneumonia were age, gender, deprivation and underlying comorbidities.


  • Open Access

    Co-infection in critically ill patients with COVID-19: an observational cohort study from England

    by Vadsala Baskaran, Hannah Lawrence, Louise E. Lansbury, Karmel Webb, Shahideh Safavi, Nurul I. Zainuddin, Tausif Huq, Charlotte Eggleston, Jayne Ellis, Clare Thakker, et al.

    Introduction. During previous viral pandemics, reported co-infection rates and implicated pathogens have varied. In the 1918 influenza pandemic, a large proportion of severe illness and death was complicated by bacterial co-infection, predominantly Streptococcus pneumoniae and Staphylococcus aureus . Gap statement. A better understanding of the incidence of co-infection in patients with COVID-19 infection and the pathogens involved is necessary for effective antimicrobial stewardship. Aim. To describe the incidence and nature of co-infection in critically ill adults with COVID-19 infection in England. Methodology. A retrospective cohort study of adults with COVID-19 admitted to seven intensive care units (ICUs) in England up to 18 May 2020, was performed. Patients with completed ICU stays were included. The proportion and type of organisms were determined at 48 h following hospital admission, corresponding to community and hospital-acquired co-infections. Results. Of 254 patients studied (median age 59 years (IQR 49–69); 64.6 % male), 139 clinically significant organisms were identified from 83 (32.7 %) patients. Bacterial co-infections/ co-colonisation were identified within 48 h of admission in 14 (5.5 %) patients; the commonest pathogens were Staphylococcus aureus (four patients) and Streptococcus pneumoniae (two patients). The proportion of pathogens detected increased with duration of ICU stay, consisting largely of Gram-negative bacteria, particularly Klebsiella pneumoniae and Escherichia coli . The co-infection/ co-colonisation rate >48 h after admission was 27/1000 person-days (95 % CI 21.3–34.1). Patients with co-infections/ co-colonisation were more likely to die in ICU (crude OR 1.78,95 % CI 1.03–3.08, P=0.04) compared to those without co-infections/ co-colonisation. Conclusion. We found limited evidence for community-acquired bacterial co-infection in hospitalised adults with COVID-19, but a high rate of Gram-negative infection acquired during ICU stay.


  • Open Access

    Primary care consultations after hospitalisation for pneumonia: a large population-based cohort study

    by Vadsala Baskaran, Fiona Pearce, Rowan H Harwood, Tricia M McKeever, Wei Shen Lim

    Background: Up to 70% of patients report ongoing symptoms 4 weeks after hospitalisation for pneumonia; the impact on primary care is poorly understood.Aim: To investigate the frequency of primary care consultations after hospitalisation for pneumonia, and the reasons for consultation.Design and setting: A population-based cohort study in England using a UK primary care database of anonymised medical records (Clinical Practice Research Datalink [CPRD]) linked to Hospital Episode Statistics (HES).Method: Adults with the first International Classification of Diseases, 10th Revision (ICD-10) code for pneumonia (J12–J18) recorded in HES between July 2002 and June 2017 were included. Primary care consultation within 30 days of discharge was identified as the recording of any medical Read code (excluding administration-related codes) in CPRD. Competing-risks regression analyses were conducted to determine the predictors of consultation and antibiotic use at consultation; death and readmission were competing events. Reasons for consultation were examined.Results: Of 56 396 adults, 55.9% (n = 31 542) consulted primary care within 30 days of hospital discharge. The rate of consultation was highest within 7 days (4.7 per 100 person–days). The strongest predictor for consultation was a higher number of primary care consultations in the year before index admission (adjusted subhazard ratio [sHR] 8.98, 95% confidence interval [CI] = 6.42 to 12.55). The most common reason for consultation was for a respiratory disorder (40.7%, n = 12 840), 11.8% for pneumonia specifically. At consultation, 31.1% (n = 9823) received further antibiotics. Penicillins (41.6%, n = 5753/13 829) and macrolides (21.9%, n = 3029/13 829) were the most common antibiotics prescribed.Conclusion: Following hospitalisation for pneumonia, a significant proportion of patients consulted primary care within 30 days, highlighting the morbidity experienced by patients during recovery from pneumonia.


  • Open Access

    Co-infection in critically ill patients with COVID-19: An observational cohort study from England

    by Vadsala Baskaran, Hannah Lawrence, Louise Lansbury, Karmel Webb, Shahideh Safavi, Izzah Zainuddin, Tausif Huq, Charlotte Eggleston, Jayne Ellis, Clare Thakker, et al.

    Objective: To describe the incidence and nature of co-infection in critically ill adults with COVID-19 infection in England. Methods: A retrospective cohort study of adults with COVID-19 admitted to seven intensive care units (ICUs) in England up to 18 May 2020, was performed. Patients with completed ICU stays were included. The proportion and type of organisms were determined at 48 hours following hospital admission, corresponding to community and hospital-acquired co-infections. Results: Of 254 patients studied (median age 59 years (IQR 49-69); 64.6% male), 139 clinically significant organisms were identified from 83(32.7%) patients. Bacterial co-infections were identified within 48 hours of admission in 14(5.5%) patients; the commonest pathogens were Staphylococcus aureus (four patients) and Streptococcus pneumoniae (two patients). The proportion of pathogens detected increased with duration of ICU stay, consisting largely of Gram-negative bacteria, particularly Klebsiella pneumoniae and Escherichia coli . The co-infection rate >48 hours after admission was 27/1000 person-days (95% CI 21.3-34.1). Patients with co-infections were more likely to die in ICU (crude OR 1.78,95% CI 1.03-3.08, p=0.04) compared to those without co-infections. Conclusion: We found limited evidence for community-acquired bacterial co-infection in hospitalised adults with COVID-19, but a high rate of Gram-negative infection acquired during ICU stay.


  • Open Access

    Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study

    by Hannah Lawrence, Harry Pick, Vadsala Baskaran, Priya Daniel, Chamira Rodrigo, Deborah Ashton, Rochelle C. Edwards-Pritchard, Carmen Sheppard, Seyi D. Eletu, David Litt, et al.

    Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is available in the United Kingdom to adults aged 65 years or older and those in defined clinical risk groups. We evaluated the vaccine effectiveness (VE) of PPV23 against vaccine-type pneumococcal pneumonia in a cohort of adults hospitalised with community-acquired pneumonia (CAP). Using a case-control test-negative design, a secondary analysis of data was conducted from a prospective cohort study of adults (aged ≥16 years) with CAP hospitalised at 2 university teaching hospitals in Nottingham, England, from September 2013 to August 2018. The exposure of interest was PPV23 vaccination at any time point prior to the index admission. A case was defined as PPV23 serotype-specific pneumococcal pneumonia and a control as non-PPV23 serotype pneumococcal pneumonia or nonpneumococcal pneumonia. Pneumococcal serotypes were identified from urine samples using a multiplex immunoassay or from positive blood cultures. Multivariable logistic regression was used to derive adjusted odds of case status between vaccinated and unvaccinated individuals; VE estimates were calculated as (1 − odds ratio) × 100%. Of 2,357 patients, there were 717 PPV23 cases (48% vaccinated) and 1,640 controls (54.5% vaccinated). The adjusted VE (aVE) estimate against PPV23 serotype disease was 24% (95% CI 5%–40%, p = 0.02). Estimates were similar in analyses restricted to vaccine-eligible patients (n = 1,768, aVE 23%, 95% CI 1%–40%) and patients aged ≥65 years (n = 1,407, aVE 20%, 95% CI −5% to 40%), but not in patients aged ≥75 years (n = 905, aVE 5%, 95% CI −37% to 35%). The aVE estimate in relation to PPV23/non-13-valent pneumococcal conjugate vaccine (PCV13) serotype pneumonia (n = 417 cases, 43.7% vaccinated) was 29% (95% CI 6%–46%). Key limitations of this study are that, due to high vaccination rates, there was a lack of power to reject the null hypothesis of no vaccine effect, and that the study was not large enough to allow robust subgroup analysis in the older age groups. In the setting of an established national childhood PCV13 vaccination programme, PPV23 vaccination of clinical at-risk patient groups and adults aged ≥65 years provided moderate long-term protection against hospitalisation with PPV23 serotype pneumonia. These findings suggest that PPV23 vaccination may continue to have an important role in adult pneumococcal vaccine policy, including the possibility of revaccination of older adults.


  • Meta-analysis of Acute Coronary Syndrome in Patients with Community-Acquired Pneumonia

    by Vadsala Baskaran, Shauntelle Quammie, Hannah Lawrence, Deborah Ashton, Wei Shen Lim, Tricia Mckeever

    Background: Numerous studies have identified that patients with community-acquired pneumonia (CAP) are at higher risk of developing acute coronary syndrome (ACS). We aimed to summarise the current literature to quantify the incidence of acute coronary syndrome in adults with CAP. Methods: We systematically searched MEDLINE and Embase, from inception to December 2018, to identify cohort and case-control studies in all languages. The inclusion criteria was adults with pneumonia, based on either clinico-radiological diagnosis or ICD codes. Patients with hospital-acquired pneumonia were excluded. Study quality was assessed by modified Newcastle Ottawa Scale. Pooled proportions were estimated using a random-effects model. Results: Of 10,626 studies identified for title and abstract screening, 103 studies met the inclusion criteria. 26 studies were included in the systematic review following full-text review (n=66,347 patients). Most of the included studies were of good quality; median quality score across the cohort studies was 5 out of 5 (IQR 4-5). Meta-analysis showed that the pooled incidence of ACS in-hospital and 30 days after CAP were 3.2% (95% CI 2.4-4.0%; n=17 studies) and 3.5% (95% CI 2.8-4.2%; n=25 studies) respectively. Sensitivity analysis excluding studies with selected cohorts (elderly, predominantly male or ICU admissions only) showed a higher pooled incidence for in-hospital ACS (4%, 95% CI 2.7-5.3%, n=13 studies) but unchanged for 30-day incidence. Conclusion: This meta-analysis highlights a small but important risk of ACS in patients with CAP; the in-hospital incidence of ACS was 3.2% and 30-day incidence was 3.5%.


  • Incidence of Cardiac Complications after Hospitalisation for Community Acquired Pneumonia: A Large Population-based Cohort Study

    by Vadsala Baskaran, Tricia Mckeever, Wei Shen Lim

    Community acquired pneumonia (CAP) and cardiac complications are associated with significant morbidity and mortality. The aim of this study was to investigate the medium and long-term extra-pulmonary impact of CAP by determining the incidence of cardiac complications at different intervals after hospitalisation for CAP. Adults aged ≥18 with the first ICD-10 code for pneumonia (J12- J18) recorded in Hospital Episode Statistics (HES) between July 2002 and June 2017 were included. The primary outcome was the incidence of incipient cardiac complications at 30 days, 90 days and 1 year from the date of hospital discharge. Cardiac complications were defined as the recording of medical Read codes related to acute coronary syndrome (ACS), heart failure (HF) and arrhythmia in a primary care database of anonymised medical records from general practitioners (Clinical Practice Research Datalink) in England. Those with pre-existing HF or arrhythmia were excluded from respective analyses. There were 73,851 adults included in the study cohort. The median age of the study cohort was 75 years (IQR 59-85 years) and 49.1% were male. The highest incidence rate (100 person-years) was at 30 days after discharge from hospital: ACS 3.9, HF 9.7, arrhythmia 13.8. The 90-day incidence rate was: ACS 2.4, HF 6.4, arrhythmia 7.3 whilst the one-year incidence rate was: ACS 1.6, HF 3.4, arrhythmia 3.4. Cardiac complications, particularly HF and arrhythmias are common after hospitalisation for CAP, and they predominantly occur after 30 days of discharge. Further research is warranted to explore the potential therapeutic and preventative strategies targeting cardiac complications after CAP.


  • Top Cited Papers

    Co-infections in people with COVID-19: a systematic review and meta-analysis

    by Louise Lansbury, Benjamin Lim, Vadsala Baskaran, Wei Shen Lim